|
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
|
01 May 2018 |
|
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
|
25 April 2018 |
|
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
|
17 April 2018 |
|
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
|
09 April 2018 |
|
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
|
23 March 2018 |
|
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
|
20 March 2018 |
|
Novartis announces changes to the Executive Committee to support strategic priorities
|
12 March 2018 |
|
Novartis expands alliance with Science 37 to advance virtual clinical trials program
|
09 March 2018 |
|
Novartis' Xolair® recommended in new global chronic urticaria guideline
|
06 March 2018 |
|
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
|
01 March 2018 |